Mico BioMed Meets New Owner, Strengthens Bio Capabilities Through Appointment of New Board Members

Mico BioMed announced on the 5th that it will hold an extraordinary general meeting of shareholders on the 26th to appoint new board members to strengthen its capabilities in new bio-businesses and to add new business objectives.

At this extraordinary general meeting, key agendas including the appointment of 4 inside directors, 3 outside directors, and 1 auditor, as well as the addition of a total of 19 business objectives, will be resolved. Through this, Mico BioMed plans to expand new businesses and enhance its global competitiveness.

The company intends to expand its business areas and strengthen its capabilities by focusing on research and development and commercialization in various fields such as bio, pharmaceuticals, health functional foods, and nanotechnology. The main additional business objectives include ▲creation of new substances ▲development of protein and peptide-based drugs ▲production of raw materials using biotechnology, as well as innovative projects such as ▲development of diagnostics and therapeutics utilizing nanotechnology ▲research and development of cell therapies and materials.

Additionally, Mico BioMed plans to focus on the development and import/export of various bio-related products, including research kits using biotechnology, diagnostic kits for animals, and distribution and sales of cell therapies.

A representative of Mico BioMed stated, “We plan to further expand our presence in domestic and international markets and secure differentiated competitiveness,” adding, “The appointment of new board members and the addition of business objectives will be an important turning point leading to innovative growth in the new bio-business sector.”